Trastuzumab biosimilar in early breast cancer setting: Will there be direct patient benefits?
| dc.contributor.author | Chan, Arlene | |
| dc.date.accessioned | 2017-11-24T05:24:50Z | |
| dc.date.available | 2017-11-24T05:24:50Z | |
| dc.date.created | 2017-11-24T04:48:52Z | |
| dc.date.issued | 2017 | |
| dc.identifier.citation | Chan, A. 2017. Trastuzumab biosimilar in early breast cancer setting: Will there be direct patient benefits?. Chinese Clinical Oncology. 6 (5). | |
| dc.identifier.uri | http://hdl.handle.net/20.500.11937/58267 | |
| dc.identifier.doi | 10.21037/cco.2017.10.03 | |
| dc.title | Trastuzumab biosimilar in early breast cancer setting: Will there be direct patient benefits? | |
| dc.type | Journal Article | |
| dcterms.source.volume | 6 | |
| dcterms.source.number | 5 | |
| dcterms.source.issn | 2304-3865 | |
| dcterms.source.title | Chinese Clinical Oncology | |
| curtin.department | Curtin Medical School | |
| curtin.accessStatus | Fulltext not available |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||